Replies to post #223223 on Biotech Values

[DewDiligence]

RVNC—I am waiting to see if insiders participate in this offering.

Insiders didn’t participate in the offering, but they are significant shareholders collectively.

See the table of insider ownership on page 21 of the 2018 annual meeting proxy (https://www.sec.gov/Archives/edgar/data/1479290/000147929018000056/rvnc2018proxystatement.htm . These ownership percentages are out of date, but the main point (above) still pertains.

[biotech jim]

I believe the RVNC thesis remains intact. I also believe they need a partner for appropriate market penetration with speed. Timing/pricing of this offering was poor, no doubt. My time frames for holding biotech stocks has been reduced in the past couple of years, too much roller coastering. This could likely be the same.

Pre-commercial companies frequently obtain poor offerings prices, but in hindsight may be a reasonable insurance policy. We shall see. But the best time to raise $$ is when it is not needed, or when the market perceives it is not needed.

I would not be surprised to see biotech offerings dry up in 2019 due to pricing constraints.